Swiss Life Asset Management Ltd Sells 26,035 Shares of Johnson & Johnson $JNJ

Key Points

• Swiss Life Asset Management trimmed its stake in Johnson & Johnson by 2.0%, selling 26,035 shares and retaining 1,268,409 shares (about $235.19 million), representing 1.2% of its portfolio and J&J as its 12th largest holding.
• Company insiders sold a total of 30,142 shares last quarter (≈$7.36 million), including EVP Vanessa Broadhurst and EVP Timothy Schmid, who significantly reduced their individual holdings.
• Positive catalysts include the FDA approval of Icotyde and several analyst price‑target increases, contributing to a MarketBeat consensus of "Moderate Buy" with a $236.91 target.

Swiss Life Asset Management Ltd trimmed its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 2.0% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,268,409 shares of the company's stock after selling 26,035 shares during the quarter. Johnson & Johnson accounts for 1.2% of Swiss Life Asset Management Ltd's portfolio, making the stock its 12th biggest holding. Swiss Life Asset Management Ltd owned about 0.05% of Johnson & Johnson worth $235,188,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently modified their holdings of JNJ. Norges Bank bought a new stake in Johnson & Johnson during the 2nd quarter valued at about $4,877,174,000. Laurel Wealth Advisors LLC grew its holdings in shares of Johnson & Johnson by 15,040.6% during the second quarter. Laurel Wealth Advisors LLC now owns 7,420,699 shares of the company's stock valued at $1,133,512,000 after buying an additional 7,371,687 shares during the last quarter. Capital International Investors grew its holdings in shares of Johnson & Johnson by 545.6% during the third quarter. Capital International Investors now owns 3,865,050 shares of the company's stock valued at $716,657,000 after buying an additional 3,266,354 shares during the last quarter. Amundi increased its position in shares of Johnson & Johnson by 19.3% during the third quarter. Amundi now owns 13,354,936 shares of the company's stock valued at $2,512,719,000 after acquiring an additional 2,163,838 shares in the last quarter. Finally, Marshall Wace LLP raised its holdings in Johnson & Johnson by 126.3% in the 3rd quarter. Marshall Wace LLP now owns 3,584,162 shares of the company's stock worth $664,575,000 after acquiring an additional 2,000,609 shares during the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, EVP Vanessa Broadhurst sold 6,197 shares of the company's stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the completion of the sale, the executive vice president directly owned 23,003 shares of the company's stock, valued at approximately $5,598,700.17. This represents a 21.22% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Timothy Schmid sold 22,623 shares of the stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $244.33, for a total transaction of $5,527,477.59. Following the completion of the transaction, the executive vice president owned 26,769 shares in the company, valued at $6,540,469.77. The trade was a 45.80% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 30,142 shares of company stock worth $7,360,528 in the last quarter. Company insiders own 0.16% of the company's stock.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: FDA approves Icotyde — expands J&J’s immunology/new drug portfolio with the first oral IL‑23 receptor antagonist, creating multi‑billion dollar revenue potential and unlocking milestone/royalty pathways with partners. Johnson & Johnson announces U.S. FDA approved Icotyde
• Positive Sentiment: Bullish analyst support — HSBC raised its price target to $280 (Buy) and Morgan Stanley reiterated a Buy with a $262 target, reinforcing upside expectations for J&J’s immunology growth. These firm-level views support longer‑term upside. HSBC Raises Johnson & Johnson Price Target TipRanks / Morgan Stanley note
• Neutral Sentiment: Clinical collaboration for prostate cancer — J&J signed a clinical‑supply agreement with GI Innovation to test a combo therapy in mCRPC (Phase 1b). Early‑stage, potentially value‑creating but long horizon. GI Innovation Announces First Clinical Supply Agreement
• Neutral Sentiment: Barclays raised its price target to $234 but kept an Equal Weight rating — a modest constructive signal, though the rating implies limited near‑term upside from current levels. Barclays Sees Continued Strength in J&J Pharma Business
• Neutral Sentiment: Partner (Protagonist) implications — Protagonist Therapeutics shares have rallied on Icotyde approval news because of milestone/royalty potential; that upside can translate into contingent payments to J&J’s partners but is secondary to J&J’s own sales path. Protagonist Therapeutics Stock Rallies Nearly 7%
• Negative Sentiment: Profit‑taking and macro skepticism — after a large run‑up in JNJ shares, investors appear to be trimming positions; market‑level concerns (stagflation commentary from influential voices) and cautious broker ratings (Equal Weight from Barclays) likely pressured the stock despite the positive product and analyst news. Jim Cramer on Johnson & Johnson

Analyst Ratings Changes

JNJ has been the topic of several recent analyst reports. JPMorgan Chase & Co. increased their target price on Johnson & Johnson from $225.00 to $250.00 and gave the company a "neutral" rating in a research note on Thursday, March 5th. Rothschild & Co Redburn upped their price target on Johnson & Johnson from $180.00 to $210.00 and gave the company a "neutral" rating in a report on Thursday, February 19th. TD Cowen increased their price objective on Johnson & Johnson from $222.00 to $250.00 and gave the company a "buy" rating in a research report on Thursday, January 22nd. Wells Fargo & Company lifted their price objective on Johnson & Johnson from $230.00 to $240.00 and gave the stock an "overweight" rating in a report on Thursday, January 22nd. Finally, Loop Capital set a $220.00 target price on shares of Johnson & Johnson in a research note on Tuesday, January 27th. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and nine have given a Hold rating to the company's stock. Based on data from MarketBeat.com, Johnson & Johnson has a consensus rating of "Moderate Buy" and a consensus target price of $236.91.

Johnson & Johnson Price Performance

NYSE JNJ opened at $235.64 on Friday. The stock has a market capitalization of $567.57 billion, a price-to-earnings ratio of 21.32, a PEG ratio of 2.35 and a beta of 0.34. Johnson & Johnson has a 1-year low of $141.50 and a 1-year high of $251.71. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.03 and a quick ratio of 0.77. The business's fifty day moving average price is $235.21 and its 200-day moving average price is $208.38.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings data on Saturday, January 31st. The company reported $2.46 EPS for the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%.The company had revenue of $24.28 billion during the quarter. On average, equities analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th were given a dividend of $1.30 per share. The ex-dividend date of this dividend was Tuesday, February 24th. This represents a $5.20 annualized dividend and a dividend yield of 2.2%. Johnson & Johnson's dividend payout ratio is presently 47.06%.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.